miR-133 involves in lung adenocarcinoma cell metastasis by targeting FLOT2

References

• Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–1245.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA: Cancer J Clin. 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Wan L, Zhu L, Xu J, et al. MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem. 2014;34:1273–1290.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32:839–851.
   PubMed Web of Science ®Google Scholar
• Li Z, Lei H, Luo M, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18:43–54.
   PubMed Web of Science ®Google Scholar
• Xiao X, Tang C, Xiao S, et al. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res. 2013;20:537–544.
   PubMed Web of Science ®Google Scholar
• Yang X, Ni W, Lei K. miR-200b suppresses cell growth, migration and invasion by targeting Notch1 in nasopharyngeal carcinoma. Cell Physiol Biochem. 2013;32:1288–1298.
   PubMed Web of Science ®Google Scholar
• Liu Z, Mai C, Yang H, et al. Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers. J Cell Mol Med. 2014;18:1667–1679.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Pang M, Dong W, et al. miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 2014;31:1473–1479.
   PubMed Web of Science ®Google Scholar
• Xie L, Yang Z, Li G, et al. Genome-wide identification of bone metastasis-related microRNAs in lung adenocarcinoma by high-throughput sequencing. PLoS One. 2013;8:e61212.
   PubMed Web of Science ®Google Scholar
• Huang JY, Cui SY, Chen YT, et al. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 2013;8:e72615.
   PubMed Web of Science ®Google Scholar
• Song Q, Xu Y, Yang C, et al. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 2014;74:3031–3042.
   PubMed Web of Science ®Google Scholar
• Tao J, Wu D, Xu B, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27:1967–1975.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 2013;47:423–432.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Liu F, Wang G, et al. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. Cell Signal. 2014;26:2667–2673.
   PubMed Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–333.
   PubMed Web of Science ®Google Scholar
• Wang YL, Yao WJ, Guo L, et al. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015;8:601–607.
   PubMed Web of Science ®Google Scholar
• Xie G, Li J, Chen J, et al. Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling. Oncol Rep. 2015;33:2285–2290.
   PubMed Web of Science ®Google Scholar
• Xu JQ, Zhang WB, Wan R, et al. MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35:9847–9853.
   PubMed Web of Science ®Google Scholar
• Long H, Wang Z, Chen J, et al. microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). Oncotarget. Nov 17 2015;6:38705–38718.
   PubMedGoogle Scholar
• Hwang SJ, Lee HW, Kim HR, et al. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget. 2015;6:20434–20448.
   PubMed Web of Science ®Google Scholar
• Babuke T, Tikkanen R. Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol. 2007;86:525–532.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang Q, Guo L, et al. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013;11:190.
   PubMed Web of Science ®Google Scholar
• Yan Y, Yang FQ, Zhang HM, et al. Up-regulation of flotillin-2 is associated with renal cell carcinoma progression. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35:10479–10486.
   PubMed Web of Science ®Google Scholar
• Liu R, Xie H, Luo C, et al. Identification of FLOT2 as a novel target for microRNA-34a in melanoma. J Cancer Res Clin Oncol. 2015;141:993–1006.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin L, Huang Z, et al. High expression of flotillin-2 is associated with poor clinical survival in cervical carcinoma. Int J Clin Exp Pathol. 2015;8:622–628.
   PubMed Web of Science ®Google Scholar
• Arkhipova KA, Sheyderman AN, Laktionov KK, et al. Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer. 2014;14:100.
   PubMed Web of Science ®Google Scholar
• Berger T, Ueda T, Arpaia E, et al. Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene. 2013;32:4989–4994.
   PubMed Web of Science ®Google Scholar
• Wu X, Sun L, Wang X, et al. Breast cancer invasion and metastasis by mPRalpha through the PI3K/Akt signaling pathway. Pathol Oncol Res. 2016;22:471–476.
   PubMed Web of Science ®Google Scholar